Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity
暂无分享,去创建一个
J. Schulz | L. Leng | R. Bucala | P. Nawroth | A. Bierhaus | P. Teismann | B. Weigle | H. Martin | K. Sathe
[1] R. Donato,et al. S100B/RAGE-dependent activation of microglia via NF-κB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1β and TNF-α , 2010, Neurobiology of Aging.
[2] J. Moreno,et al. Suppression of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Nitric-Oxide Synthase 2 Expression in Astrocytes by a Novel Diindolylmethane Analog Protects Striatal Neurons against Apoptosis , 2009, Molecular Pharmacology.
[3] K. Tracey,et al. The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage , 2008, The Journal of Neuroscience.
[4] J. Moreno,et al. Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level inflammatory stimulation with MPTP , 2008, Brain Research.
[5] Howard E. Gendelman,et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.
[6] H. Kato,et al. Time dependent alterations of co-localization of S100β and GFAP in the MPTP-treated mice , 2006, Journal of Neural Transmission.
[7] Isidre Ferrer,et al. Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease , 2005, Journal of neuropathology and experimental neurology.
[8] Kevin J. Tracey,et al. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.
[9] Vladimir V. Frolkis,et al. Neurobiology of Aging , 2019, Psychobiology of Behaviour.
[10] V. Arolt,et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury , 2004, Neuroscience.
[11] J. Schneider,et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. , 2004, The Journal of clinical investigation.
[12] J. Schulz,et al. Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation , 2004, Cell and Tissue Research.
[13] M. Vila,et al. L‐3‐hydroxyacyl‐CoA dehydrogenase II protects in a model of Parkinson's disease , 2004, Annals of neurology.
[14] L. J. Eldik,et al. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production , 2004, Neurobiology of Aging.
[15] Pasko Rakic,et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. Dichgans,et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. , 2004, Journal of neurochemistry.
[17] J. Dichgans,et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation , 2003 .
[18] T. Araki,et al. Expression of S‐100 protein is related to neuronal damage in MPTP‐treated mice , 2003, Glia.
[19] M. Vila,et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] Dong-Kug Choi,et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] A. Schmidt,et al. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. , 2002, Advanced drug delivery reviews.
[22] H. Freeze,et al. N‐Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth , 2002, Journal of neurochemistry.
[23] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[24] M. Andrassy,et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.
[25] L. J. Eldik,et al. S100B proteins that lack one or both cysteine residues can induce inflammatory responses in astrocytes and microglia , 2001, Neurochemistry International.
[26] A. Schmidt,et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.
[27] F. Weih,et al. Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. , 2001, Neuroreport.
[28] G. Petzinger,et al. The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.
[29] H. Huttunen,et al. Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) Activation* , 2000, The Journal of Biological Chemistry.
[30] P. Riederer,et al. Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.
[31] J. Dichgans,et al. Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.
[32] K. Unsicker,et al. GDNF and NT-4 Protect Midbrain Dopaminergic Neurons from Toxic Damage by Iron and Nitric Oxide , 2000, Experimental Neurology.
[33] S. Barger,et al. S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons , 2000, Journal of neurochemistry.
[34] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[35] T. Kislinger,et al. N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.
[36] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[37] R. Donato,et al. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. , 1999, Biochimica et biophysica acta.
[38] M. Neurath,et al. RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.
[39] E. Hirsch,et al. FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells , 1999, The Journal of Neuroscience.
[40] C. Sen,et al. Nuclear factor kappa B activity in response to oxidants and antioxidants. , 1999, Methods in enzymology.
[41] E. Hirsch,et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[42] C. Kerkhoff,et al. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). , 1998, Biochimica et biophysica acta.
[43] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[44] Y Agid,et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[45] C. Kaltschmidt,et al. NF-kB: a crucial transcription factor for glial and neuronal cell function , 1997, Trends in Neurosciences.
[46] C. Kaltschmidt,et al. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. , 1997, Trends in neurosciences.
[47] X. Chen,et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.
[48] A. Schmidt,et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.
[49] G. Otto,et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.
[50] D. Baltimore,et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. , 1995, Nature.
[51] Y. Zou,et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.
[52] R. Bucala,et al. Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.
[53] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[54] D. Reis,et al. Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum , 1981, Brain Research.
[55] V. Tennyson,et al. 5-Hydroxydopamine 'tagged' neuronal boutons in rabbit neostriatum: interrelationship between vesicles and axonal membrane. , 1974, Brain research.